<SEC-DOCUMENT>0000912057-19-000215.txt : 20190814
<SEC-HEADER>0000912057-19-000215.hdr.sgml : 20190814
<ACCEPTANCE-DATETIME>20190513094909
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000912057-19-000215
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="295" height="24" src="g37296bgi001.gif"></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">599 Lexington Avenue<br> New York, NY 10022-6069</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">+1.212.848.4000</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">May&nbsp;13, 2019</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><u><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CONFIDENTIAL SUBMISSION VIA EDGAR</font></u></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Securities and Exchange Commission</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Office of Healthcare&nbsp;&amp; Insurance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Division of Corporation Finance</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100 F Street, N.E.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Washington, D.C. 20549</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Attn: Tonya K. Aldave, Dietrich King,&nbsp;Isaac Esquivel and Kate Tillan</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Re:</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Genmab A/S</b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Amendment No.&nbsp;1 to Draft Registration Statement on Form&nbsp;F-1</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Submitted on April&nbsp;2, 2019</font></b></p>
<p style="margin:0in 0in .0001pt .5in;text-indent:.5in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CIK No.&nbsp;0001434265</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Ladies and Gentlemen:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On behalf of our client Genmab A/S (the &#147;<u>Company</u>&#148;), we are submitting this letter in response to the written comments of the staff (the &#147;<u>Staff</u>&#148;) of the Securities and Exchange Commission (the &#147;<u>SEC</u>&#148;), as contained in your letter dated April&nbsp;11, 2019 (the &#147;<u>Comment Letter</u>&#148;) to the Company regarding the Company&#146;s above-referenced Amendment No.&nbsp;1 to the draft registration statement (CIK No.&nbsp;0001434265) on Form&nbsp;F-1 confidentially submitted to the SEC on April&nbsp;2, 2019 (the &#147;<u>Form&nbsp;F-1</u>&#148;).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To facilitate your review of the Company&#146;s responses, we have repeated each of your comments in italics followed immediately by the response of the Company to that particular comment.&#160; Simultaneously with the transmission of this letter, the Company is confidentially submitting via EDGAR an amendment (&#147;<u>Amendment No.&nbsp;2</u>&#148;) to the Form&nbsp;F-1 (as so amended, the &#147;<u>Registration Statement</u>&#148;), responding to the Staff&#146;s comments and including certain other revisions and updates. Please note that capitalized terms used but not otherwise defined in this letter have the meanings ascribed to such terms in Amendment No.&nbsp;2. Page&nbsp;numbers in the text of the Company&#146;s responses correspond to page&nbsp;numbers in Amendment No.&nbsp;2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*****</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SHEARMAN.COM</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Shearman&nbsp;&amp; Sterling LLP is a limited liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal liability of partners.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\C905656\19-3729-6\task9356790\3729-6-bg.htm',USER='C905656',CD='May 13 05:03 2019' -->

<div style="page-break-before:always;"></div>
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amendment No.&nbsp;1 to Draft Registration Statement on Form&nbsp;F-1</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Capitalization, page&nbsp;73</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 41.05pt;text-indent:-35.3pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">1.</font></i><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>Please tell us why it is appropriate to include total liabilities in your capitalization table when it appears that you have no long-term debt or other long-term liabilities.</i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In response to the Staff&#146;s comment, the Company has revised its disclosure on page&nbsp;76 of Amendment No.&nbsp;2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Business</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Medarex UltiMAb System License, page&nbsp;161</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 40.8pt;text-indent:-35.3pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">2.</font></i><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><i>We note your response to comment 12.&#160; Please disclose the aggregate value of the per-product milestone payments remaining under this agreement.</i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In response to the Staff&#146;s comment, the Company has revised its disclosure on page&nbsp;171 of Amendment No.&nbsp;2.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">*****</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We thank the Staff in advance for its consideration of Amendment No.&nbsp;2 and hope the Staff finds that the foregoing answers are responsive to its comments. If you should have any questions or further comments with respect to the Registration Statement, please do not hesitate to contact me at (212) 848-7150.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Very   truly yours,</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Harald Halbhuber</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Harald   Halbhuber</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">cc:</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>David Eatwell, Chief Financial Officer, Genmab A/S</p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nathan Ajiashvili, Latham&nbsp;&amp; Watkins LLP</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_052423_33"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C905656\19-3729-6\task9356790\3729-6-bg.htm',USER='C905656',CD='May 13 05:03 2019' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g37296bgi001.gif
<TEXT>
begin 644 g37296bgi001.gif
M1TE&.#=A)P$8 '<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MR0""3P81#( P\!,"4,T*.@4U %S5!$P--@LPX #"3U:M#HB"M""$ . "E 5
M))35J =##5B*,,&  %F)! !5[]]""%$,$ !U@$A#P ;V&0A0>"!@4*#"#G@F
M8" 1NY('("A(I.H J@C@%N1J^""$9X3-*A5]X-E1@TX]$3 0)2M"" G4(FPV
M( %"MW.M)BB-D$C;JN"L-B:X=^U6 P4*;@4'F2I6@T0.5 VU.WE5JJ&("_^$
M$-F.5X%$HB0_;U ]]+K4"QC7"RY4Y81$"NPU0-LVPG_Y/9/<-*!<-YY=D1E
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%^R0@ #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
